Actis acquires Hyderabad-based Rx Propellant for an undisclosed amount
Global investor Actis has acquired Hyderabad-based Rx Propellant, which provides real estate solutions to tenants in life sciences and related sectors.
Rx Propellant is a leading player in the life sciences real estate sector. It is currently involved in development and marketing of a number of real estate projects in design-development stage across Hyderabad and Bangalore targeted at life sciences sector users, aggregating over 3 million square feet, the company said in a statement.
The deal value was not disclosed.
Brian Chinappi, Partner and Global Head of Real Estate at Actis, said: “The life sciences sector in India is already of global strategic importance, as demonstrated during the Covid-19 pandemic. It is poised for significant growth, owing to a confluence of a number of factors both local and global.”
Ashish Singh, Partner and Head of India and SE Asia Real Estate at Actis, said: “Life sciences corporations have unique requirements and often need customised real estate solutions which are deficient in supply.”
The Rx Propellant looks to fill this gap, and help support India-bound drug discovery and manufacturing programmes by providing customised real estate solutions, he added.
“In the initial phase, Actis is looking to invest USD 200 million (around Rs 1,550 crore) into a buy & build program targeting both greenfield and brownfield assets with an emphasis on sustainability.”
Rx Propellant will focus on thriving life sciences clusters in Hyderabad, Bangalore and Mumbai.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
